DERM Earnings

DERM reported its earnings on 2026-03-19, showcasing a revenue of against an estimate of 19.07M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.05 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following DERM's earnings announcement on 2026-03-19, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, DERM's stock price tends to shift by an average of 0.12% in the 10 days leading up to earnings and 6.07% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate DERM's annual revenue to reach 19.34M, while the EPS is projected at -0.04. These estimates reflect recent revisions, with revenue estimates revised downward by -0.01% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between DERM's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised downward by -0.01%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, DERM's stock price typically moves by 0.12% in the 10 days before its earnings and 6.07% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.04 and revenue of 19.34M.

The earnings call reveals strong revenue growth driven by EMROSI, improved EBITDA, and positive cash flow. The Q&A section highlights successful prescriber expansion and revenue per script improvements, although there are concerns about gross-to-net revenue guidance and prescriber retention data. Despite these uncertainties, the overall sentiment is positive due to the strong financial metrics, optimistic guidance, and strategic focus on expanding EMROSI's market presence.